Advancing respiratory virus diagnostics: integrating the nasal IFN-I score for improved viral detection.

IF 9.7 1区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

EBioMedicine Pub Date : 2024-11-21 DOI:10.1016/j.ebiom.2024.105450

Marine Mommert-Tripon, Delphine Parraud, Cloé Grosbois, Alexandre Gaymard, Valérie Cheynet, Bruno Lina, Guy Oriol, Frédéric Laurent, Caroline Dupré, Quentin Semanas, Antonin Bal, Laurence Generenaz, Sylvie Pons, Karen Brengel-Pesce, Audrey Guichard, William Mouton, Florence Morfin, Aurore Fleurie, Sophie Trouillet-Assant

{"title":"Advancing respiratory virus diagnostics: integrating the nasal IFN-I score for improved viral detection.","authors":"Marine Mommert-Tripon, Delphine Parraud, Cloé Grosbois, Alexandre Gaymard, Valérie Cheynet, Bruno Lina, Guy Oriol, Frédéric Laurent, Caroline Dupré, Quentin Semanas, Antonin Bal, Laurence Generenaz, Sylvie Pons, Karen Brengel-Pesce, Audrey Guichard, William Mouton, Florence Morfin, Aurore Fleurie, Sophie Trouillet-Assant","doi":"10.1016/j.ebiom.2024.105450","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to demonstrate the utility of the nasal Type I interferon (IFN-I) response as a marker for respiratory viral infections (RVIs) and its potential to enhance diagnosis when combined with first-line PCR tests for Influenza A/B, RSV, and SARS-CoV-2.Methods: Nasopharyngeal swabs (NPS) from patients at Hospices Civils de Lyon (November 2022-April 2024) suspected of viral infections (n = 788) and from healthy controls (n = 53) were analysed. The IFN-I score was measured using the FILMARRAY® IFN-I pouch prototype, which detects four interferon-stimulated genes. The study evaluated the performance of the IFN-I score in detecting samples positive for viruses by first-line PCR and assessed its benefit in diagnosing RVIs in samples initially classified as negative by PCR.Findings: Out of 788 NPS included, 504 (64%) were positive with the first-line PCR tests, and IFN-I score was significantly higher in those samples (median [IQR]: 13.00 [2.76-45.40]) compared to ones collected from healthy controls (1.09 [0.67-1.30]; p < 0.0001), with an area under the curve (AUC; 95% CI) of 0.92 (0.90-0.92). Moreover, out of the 284 NPS negative with first-line PCR tests, suspicion of viral infection according to IFN-I score was found in 63% of cases (178/284). Second-line test (BioFire® Respiratory Panel 2.1 plus) and viral metagenomic confirmed the presence of viruses 94% of cases.Interpretation: The study highlights the potential of integrating nasal IFN-I score into clinical workflows to improve RVI diagnosis and enhance preparedness for emerging viruses.Funding: Public grant overseen by the French National Research Agency (ANR21-RHUS-08/ANR-23-CHIN-0001).","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"110 ","pages":"105450"},"PeriodicalIF":9.7000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EBioMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ebiom.2024.105450","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to demonstrate the utility of the nasal Type I interferon (IFN-I) response as a marker for respiratory viral infections (RVIs) and its potential to enhance diagnosis when combined with first-line PCR tests for Influenza A/B, RSV, and SARS-CoV-2.

Methods: Nasopharyngeal swabs (NPS) from patients at Hospices Civils de Lyon (November 2022-April 2024) suspected of viral infections (n = 788) and from healthy controls (n = 53) were analysed. The IFN-I score was measured using the FILMARRAY® IFN-I pouch prototype, which detects four interferon-stimulated genes. The study evaluated the performance of the IFN-I score in detecting samples positive for viruses by first-line PCR and assessed its benefit in diagnosing RVIs in samples initially classified as negative by PCR.

Findings: Out of 788 NPS included, 504 (64%) were positive with the first-line PCR tests, and IFN-I score was significantly higher in those samples (median [IQR]: 13.00 [2.76-45.40]) compared to ones collected from healthy controls (1.09 [0.67-1.30]; p < 0.0001), with an area under the curve (AUC; 95% CI) of 0.92 (0.90-0.92). Moreover, out of the 284 NPS negative with first-line PCR tests, suspicion of viral infection according to IFN-I score was found in 63% of cases (178/284). Second-line test (BioFire® Respiratory Panel 2.1 plus) and viral metagenomic confirmed the presence of viruses 94% of cases.

Interpretation: The study highlights the potential of integrating nasal IFN-I score into clinical workflows to improve RVI diagnosis and enhance preparedness for emerging viruses.

Funding: Public grant overseen by the French National Research Agency (ANR21-RHUS-08/ANR-23-CHIN-0001).

查看原文本刊更多论文

推进呼吸道病毒诊断：结合鼻腔 IFN-I 评分改进病毒检测。

研究背景本研究旨在证明鼻腔 I 型干扰素（IFN-I）反应作为呼吸道病毒感染（RVI）标志物的实用性，以及将其与甲型/乙型流感、RSV 和 SARS-CoV-2 的一线 PCR 检测相结合以提高诊断率的潜力：分析了里昂平民医院（Hospices Civils de Lyon）疑似病毒感染患者（788 人）和健康对照组（53 人）（2022 年 11 月至 2024 年 4 月）的鼻咽拭子（NPS）。IFN-I评分使用FILMARRAY® IFN-I小袋原型进行测量，该小袋可检测四种干扰素刺激基因。研究评估了 IFN-I 评分在通过一线 PCR 检测病毒阳性样本方面的性能，并评估了它在诊断 PCR 初步归类为阴性的样本中的 RVIs 方面的益处：在纳入的 788 份 NPS 中，有 504 份（64%）在一线 PCR 检测中呈阳性，这些样本的 IFN-I 评分（中位数 [IQR]：13.00 [2.76-45.40]）明显高于从健康对照组采集的样本（1.09 [0.67-1.30]；p 解释：IFN-I 评分的中位数[IQR]：13.00 [2.76-45.40]）：该研究强调了将鼻腔IFN-I评分纳入临床工作流程的潜力，以改善RVI诊断并提高对新出现病毒的防范能力：由法国国家研究署监管的公共基金（ANR21-RHUS-08/ANR-23-CHIN-0001）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EBioMedicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology

CiteScore

17.70

自引率

0.90%

发文量

579

审稿时长

5 weeks

期刊介绍： eBioMedicine is a comprehensive biomedical research journal that covers a wide range of studies that are relevant to human health. Our focus is on original research that explores the fundamental factors influencing human health and disease, including the discovery of new therapeutic targets and treatments, the identification of biomarkers and diagnostic tools, and the investigation and modification of disease pathways and mechanisms. We welcome studies from any biomedical discipline that contribute to our understanding of disease and aim to improve human health.